BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 24443998)

  • 21. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
    Thompson BA; Martins A; Spurdle AB
    Clin Genet; 2015 Feb; 87(2):100-8. PubMed ID: 24989436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response.
    Meijer TW; Hoogerbrugge N; Nagengast FM; Ligtenberg MJ; van Krieken JH
    Histopathology; 2009 Oct; 55(4):414-22. PubMed ID: 19817892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
    Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
    BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.
    Bakry D; Aronson M; Durno C; Rimawi H; Farah R; Alharbi QK; Alharbi M; Shamvil A; Ben-Shachar S; Mistry M; Constantini S; Dvir R; Qaddoumi I; Gallinger S; Lerner-Ellis J; Pollett A; Stephens D; Kelies S; Chao E; Malkin D; Bouffet E; Hawkins C; Tabori U
    Eur J Cancer; 2014 Mar; 50(5):987-96. PubMed ID: 24440087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.
    Mensenkamp AR; Vogelaar IP; van Zelst-Stams WA; Goossens M; Ouchene H; Hendriks-Cornelissen SJ; Kwint MP; Hoogerbrugge N; Nagtegaal ID; Ligtenberg MJ
    Gastroenterology; 2014 Mar; 146(3):643-646.e8. PubMed ID: 24333619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair gene deficiency and genetic anticipation in Lynch syndrome: myth or reality?
    Ponti G; Ruini C; Tomasi A
    Dis Colon Rectum; 2015 Jan; 58(1):141-2. PubMed ID: 25489705
    [No Abstract]   [Full Text] [Related]  

  • 33. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
    Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
    Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
    Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mismatch repair deficiency testing in clinical practice.
    Buza N; Ziai J; Hui P
    Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside.
    Boland CR; Koi M; Chang DK; Carethers JM
    Fam Cancer; 2008; 7(1):41-52. PubMed ID: 17636426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome.
    Rahner N; Friedrichs N; Wehner M; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    Acta Oncol; 2007; 46(6):763-9. PubMed ID: 17653898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.